Format

Send to

Choose Destination
J Antimicrob Chemother. 2002 Feb;49(2):415-9.

Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients.

Author information

1
Department of Medicine, Division of Geographic Medicine and Infectious Diseases, New England Medical Center, Box 041, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA. shadley@lifespan.org

Abstract

We examined the utility of a semi-solid agar antifungal susceptibility screening (SAAS) test in real-time management of eight immunocompromised patients with invasive yeast infections. Tests of amphotericin B and fluconazole concentrations of 0.5 and 2 mg/L and 1, 8 and 40 mg/L, respectively, were performed on Candida albicans (two), Candida tropicalis (two), Candida krusei (one), Candida glabrata (one) and Trichosporon species (spp.) (two). All but the Trichosporon spp. and C. glabrata isolates were resistant to fluconazole at > or = 40 mg/L, and patients were successfully managed accordingly. Real-time antifungal susceptibility screening can assist in clinical management of invasive yeast infections.

PMID:
11815592
DOI:
10.1093/jac/49.2.415
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center